Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development
Guardant Health (Nasdaq: GH) announced its participation in the ASCO Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, January 23-25, 2025, where it will present significant data on its precision oncology tools. The presentations will focus on cancer screening, recurrence monitoring, treatment selection, and therapy development.
A key highlight includes data from the phase II NEO trial demonstrating Guardant Reveal's potential as a decision tool for organ preservation in node-negative rectal cancer patients. The company will present multiple studies across its product portfolio, including Guardant360, GuardantINFORM, and Shield, covering topics such as colorectal cancer screening cost-effectiveness, genomic landscapes in various cancers, and real-world survival differences in biliary tract cancer patients.
According to Dr. Craig Eagle, Guardant Health's chief medical officer, the data supports the growing value of precision oncology tools, particularly liquid biopsy, in GI cancer detection, treatment selection, and monitoring, potentially leading to more personalized cancer care and improved patient outcomes.
Guardant Health (Nasdaq: GH) ha annunciato la sua partecipazione al Simposio ASCO sui Cancro Gastrointestinali (ASCO GI) a San Francisco, dal 23 al 25 gennaio 2025, dove presenterà dati significativi sui suoi strumenti di oncologia di precisione. Le presentazioni si concentreranno sullo screening del cancro, sul monitoraggio delle recidive, sulla selezione dei trattamenti e sullo sviluppo delle terapie.
Un punto saliente include i dati del trial NEO di fase II che dimostrano il potenziale di Guardant Reveal come strumento decisionale per la conservazione degli organi nei pazienti con cancro rettale senza coinvolgimento linfonodale. L'azienda presenterà diversi studi del suo portafoglio di prodotti, tra cui Guardant360, GuardantINFORM e Shield, trattando argomenti come l’efficacia dei costi nello screening del cancro colorettale, i paesaggi genomici in vari tumori e le differenze di sopravvivenza nel mondo reale nei pazienti con cancro delle vie biliari.
Secondo il Dr. Craig Eagle, Chief Medical Officer di Guardant Health, i dati supportano il crescente valore degli strumenti di oncologia di precisione, in particolare la biopsia liquida, nella rilevazione dei tumori gastrointestinali, nella selezione dei trattamenti e nel monitoraggio, portando potenzialmente a una cura del cancro più personalizzata e a risultati migliori per i pazienti.
Guardant Health (Nasdaq: GH) anunció su participación en el Simposio ASCO sobre Cánceres Gastrointestinales (ASCO GI) en San Francisco, del 23 al 25 de enero de 2025, donde presentará datos significativos sobre sus herramientas de oncología de precisión. Las presentaciones se centrarán en la detección del cáncer, el monitoreo de recaídas, la selección de tratamientos y el desarrollo de terapias.
Un aspecto destacado incluye datos del ensayo NEO de fase II que demuestran el potencial de Guardant Reveal como herramienta de decisión para la preservación de órganos en pacientes con cáncer rectal sin afectación ganglionar. La empresa presentará múltiples estudios de su cartera de productos, incluyendo Guardant360, GuardantINFORM y Shield, cubriendo temas como la relación costo-efectividad del tamizaje del cáncer colorrectal, paisajes genómicos en varios cánceres y diferencias de supervivencia en la vida real en pacientes con cáncer de vías biliares.
Según el Dr. Craig Eagle, director médico de Guardant Health, los datos respaldan el creciente valor de las herramientas de oncología de precisión, particularmente la biopsia líquida, en la detección, selección de tratamientos y monitoreo del cáncer gastrointestinal, lo que podría conducir a una atención del cáncer más personalizada y a mejores resultados para los pacientes.
Guardant Health (Nasdaq: GH)는 2025년 1월 23일부터 25일까지 샌프란시스코에서 열리는 ASCO 위장관 암 심포지움 (ASCO GI)에 참여한다고 발표했습니다. 이 자리에서 정밀 종양학 도구에 대한 중요한 데이터를 발표할 예정입니다. 발표는 암 선별 검사, 재발 모니터링, 치료 선택 및 치료 개발에 초점을 맞출 것입니다.
주요 하이라이트 중 하나는 2상 NEO 시험의 데이터로, Guardant Reveal이 림프절 음성 직장암 환자에서 장기 보존을 위한 결정 도구로서의 잠재력을 보여줍니다. 이 회사는 Guardant360, GuardantINFORM 및 Shield를 포함한 제품 포트폴리오 전반에 걸쳐 여러 연구를 발표할 예정이며, 대장암 선별의 비용-효과성, 다양한 암의 유전체 환경, 담도암 환자의 실제 생존 차이와 같은 주제를 다룰 것입니다.
Guardant Health의 최고 의료 책임자인 Craig Eagle 박사에 따르면, 데이터는 특히 액체 생검이 GI 암의 탐지, 치료 선택 및 모니터링에서 정밀 종양학 도구의 가치가 증가하고 있음을 뒷받침하고 있으며, 이는 보다 개인화된 암 치료와 향상된 환자 결과로 이어질 수 있습니다.
Guardant Health (Nasdaq: GH) a annoncé sa participation au Symposium ASCO sur les Cancers Gastro-Intestinaux (ASCO GI) à San Francisco, du 23 au 25 janvier 2025, où elle présentera des données significatives sur ses outils d'oncologie de précision. Les présentations porteront sur le dépistage du cancer, la surveillance des récidives, le choix des traitements et le développement de thérapies.
Un point saillant comprend des données de l'essai NEO de phase II démontrant le potentiel de Guardant Reveal en tant qu'outil décisionnel pour la préservation des organes chez les patients atteints de cancer rectal sans ganglions lymphatiques affectés. L'entreprise présentera plusieurs études de son portefeuille de produits, y compris Guardant360, GuardantINFORM et Shield, couvrant des sujets tels que le rapport coût-efficacité du dépistage du cancer colorectal, les paysages génomiques dans divers cancers et les différences de survie dans le monde réel chez les patients atteints de cancer des voies biliaires.
Selon Dr. Craig Eagle, directeur médical de Guardant Health, les données soutiennent la valeur croissante des outils d'oncologie de précision, en particulier la biopsie liquide, dans la détection, le choix des traitements et le suivi des cancers gastro-intestinaux, ce qui pourrait conduire à des soins du cancer plus personnalisés et à de meilleurs résultats pour les patients.
Guardant Health (Nasdaq: GH) gab seine Teilnahme am ASCO Symposium für Gastrointestinale Krebserkrankungen (ASCO GI) in San Francisco vom 23. bis 25. Januar 2025 bekannt, wo bedeutende Daten zu seinen Tools der Präzisionsonkologie präsentiert werden. Die Vorträge werden sich auf die Krebsvorsorge, das Monitoring von Rückfällen, die Auswahl von Behandlungen und die Therapieentwicklung konzentrieren.
Ein besonderes Highlight sind die Daten aus der Phase-II-NEO-Studie, die das Potenzial von Guardant Reveal als Entscheidungsinstrument zur Organerhaltung bei lymphknoten-negativen Rektumkarzinompatienten demonstrieren. Das Unternehmen wird mehrere Studien aus seinem Produktportfolio präsentieren, darunter Guardant360, GuardantINFORM und Shield, die Themen wie Kosten-Effektivität der Kolorektalkrebsvorsorge, genomische Landschaften in verschiedenen Krebsarten und die Unterschiede in der Überlebensrate bei Patienten mit Gallenwegkrebs im realen Leben abdecken.
Laut Dr. Craig Eagle, dem Chief Medical Officer von Guardant Health, unterstützen die Daten den wachsenden Wert von Tools der Präzisionsonkologie, insbesondere der Flüssigbiopsie, bei der Entdeckung, Auswahl von Behandlungen und Überwachung von gastrointestinalen Krebserkrankungen, was potenziell zu einer personalisierteren Krebsversorgung und verbesserten Patientenoutcomes führen könnte.
- None.
- None.
Data shared from phase II NEO trial highlights Guardant Reveal™ as a decision tool to support organ preservation in rectal cancer
Key focus areas in Guardant’s co-authored abstracts and collaborator presentations utilizing Guardant products include the impact of mutations on treatment response in colorectal cancer and biliary tract cancers, and additional support for the benefits of blood-based screening in colorectal, gastric and esophageal cancers. A rapid oral presentation will feature data from the phase II NEO trial highlighting Guardant Reveal as a decision tool to support organ preservation in patients with node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision and observation.
“Data increasingly supports the value of precision oncology tools, and specifically liquid biopsy, in detecting GI cancers, informing treatment selection, and monitoring for recurrence and therapy response,” said Craig Eagle, MD, Guardant Health chief medical officer. “Findings presented at ASCO GI demonstrate the advancements being made by Guardant Health and our partners in these areas and show the potential for these tools to provide even more personalized cancer care, leading to better patient outcomes.”
Guardant Health ASCO GI 2025 Co-Authored Posters and Presentations
Time and Location |
Title |
Abstract and Presentation Type |
Guardant Reveal |
||
January 25, 2025 9:15 – 10:00 am PST Level 2, Ballroom |
Tumour-free ctDNA detection as a decision tool to support organ preservation in node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II NEO trial (CCTG CO.28) |
Rapid Oral Abstract Session C Abstract #20 |
Guardant360® |
||
January 25, 2025 7:00 – 7:55 am PST Level 1, West Hall |
Retrospective study evaluating the genomic landscape of anal squamous cell carcinoma using liquid biopsy |
Poster Session C Abstract #8 |
Landscape of metastatic colorectal cancer (CRC) using comprehensive circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in |
Poster Session C Abstract #49 |
|
GuardantINFORM™ |
||
January 24, 2025 11:30 am – 1:00 pm PST Level 1, West Hall |
Real-world survival differences in advanced biliary tract cancer patients with ctDNA detected IDH1 mutations and FGFR2 fusions receiving first-line gemcitabine-cisplatin with and without immunotherapy |
Poster Session B Abstract #548 |
ShieldTM |
||
January 25, 2025 7:00 – 7:55 am PST Level 1, West Hall |
Cost-effectiveness of blood-based colorectal cancer screening: A simulation model incorporating real-world longitudinal adherence |
Poster Session C Abstract #93 |
A method for classifying colorectal cancer and gastric/esophageal cancer using blood-based testing |
Poster Session C Abstract #52 |
|
The full abstracts for Guardant Health and a list of all abstracts being presented at ASCO GI 2025 can be found on the ASCO website.
For information and updates from the conference, follow Guardant Health on LinkedIn, X (Twitter) and Facebook.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250123880822/en/
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Michael Weist
press@guardanthealth.com
+1 317-371-0035
Source: Guardant Health, Inc.
FAQ
What are the key findings from Guardant Health's phase II NEO trial presented at ASCO GI 2025?
When and where is Guardant Health (GH) presenting at ASCO GI 2025?
What products will Guardant Health (GH) showcase at ASCO GI 2025?
How is Guardant Health (GH) addressing cost-effectiveness in colorectal cancer screening?
What real-world data is Guardant Health (GH) presenting about biliary tract cancer?
